The Cancer Vaccine Gold Rush Has Begun. So Has the Race for Picks and Shovels.
Tempus AI could capture a lucrative slice of Moderna and Merck’s personalized cancer therapy business, with Personalis at the center of the bet.
We haven't written up this one. WSJ Markets has the full story — the link below goes straight to it.